ISAR Newsletter

July 2026

ISAR HIGHLIGHTS 2026

ISAR ACHIEVEMENTS

We celebrate **ISAR**'s recruitment of over **38,000** patients from **32** countries, with data now representing over **137,000** patient years, as well as the achievement of **43** publications and **71** abstracts.

ISAR's research has received more than **1,800** citations and continues to inform local and international clinical guidelines.

We thank all **ISAR** collaborators for their continued contributions!



ISAR PUBLICATIONS

There are **<u>seven</u> ISAR** publications so far in 2026, including multiple collaborative regional and country specific publications. Congratulations to all involved!

GLEAM I: Assessing the impact of earlier initiation of biologics on clinical remission and other outcomes in a global real-life severe asthma cohort from CHRONICLE, ISAR and OPCRD - CHEST

Earlier initiation of biologics in severe asthma is associated with better clinical outcomes, suggesting the need to modify asthma management from a 'reserve' to a 'preserve' approach: i.e., not reserving biologics for those with long-standing SA, instead preserving patients' lung function and possibly increasing the likelihood of better clinical outcomes with earlier biologic initiation.

In Press



GLEAM II: Association of easier biologic access with remission and other clinical outcomes in severe asthma: a global real-world study - J Allergy Asthma

Easier access to biologics for patients with severe asthma, a prerequisite for shorter time-to-initiation of biologic therapies, was associated with a greater probability of achieving clinical remission and other key asthma outcomes.

In Press



Longitudinal observation of severe asthma comorbidities and oral corticosteroids use from SANI and ISAR registries - WAOJ

Severe asthma patients in **Italy** had higher prevalence of T2-related comorbidities and some OCS-related comorbidities than in **ISAR** globally.

▪ ***Read full publication***



Severe asthma patients' characteristics in Mexico versus International Severe Asthma Registry (ISAR) Global - *Curr Allergy Asthma Rep*

Severe asthma patients in **Mexico** had higher prevalence of T2 comorbidities, lower prevalence of OCS-related comorbidities and higher rate of biologic use than in **ISAR** globally.

▪ ***Read full publication***



Geographical variability in severe asthma: comparison of patients' characteristics between national, regional and international cohorts in ISAR - J Asthma

Severe asthma patients in **Greece** had higher prevalence of allergic rhinitis and osteoporosis vs. Southern Europe and the global **ISAR** cohort.

▪ ***Read full publication***



Interactive Pathways of Key Prognostic Factors in Severe Asthma – A Bayesian Network Comparison of Clinical Trials and Real-World Data - CHEST

Total serum IgE level influenced BEC to predict future severe exacerbations; history of severe exacerbation directly predicted future severe exacerbations.



▪ ***Read full publication***

Development and validation of the Risk of Exacerbation in Severe Asthma (RESA) model - J Allergy Clin Immunol Pract

The Risk of Exacerbation in Severe Asthma (RESA) model uses **11** predictors to estimate exacerbation risk, highlighting the value of real-world data.

▪ ***Read full publication***



ISAR EVENTS



Over forty collaborators attended **ISAR** events (in person and online), twenty-three country meetings were held and one **ISAR** poster presented.

- **ISAR**'s achievements in patient recruitment, research and publications were highlighted.
- **ISAR**'s exciting **ENLIGHTEN** analyses were revealed, showing substantial reduction in long-term steroid use since participation in ISAR and marked improvement since access to **ISAR**'s practice change tools in 2023.
- Project updates and dissemination plans were discussed at the working group meetings for **MOONLIGHT**, investigating the impact of biologics on inhaled corticosteroid use.
- Highlights of **ISAR**'s active research projects were shared including **SPOTLIGHT**, **SHINE**, **GLEAM** and **FLAME**. Critical themes surfacing in asthma care were explored, including response and remission patterns with biologics.
- Future opportunities for **ISAR** and collaborators were explored, including Centres and Networks of Excellence
- **ISAR** Session at REG: The presentations showcased a transformative shift in severe asthma management, focusing on remission as a treatment goal, earlier biologic access, relapse prevention, and reducing long-term OCS exposure.



Over 20 global collaborators attended **ISAR** events in person, including two working group meetings, a research updates meeting, and **ISAR** industry symposium.

- **ISAR** Industry Symposium - Attended by six pharmaceutical companies, **ISAR**'s research achievements were highlighted and collaboration opportunities identified through exploring our real-world datasets, impact on practice change, and excellence in clinical trial recruitment potential.
- Exciting updates were shared at the working groups for the latest prioritised **ISAR** research studies **GLOW** and **GLISTEN**, aiming to understand patterns in biologic use and which domains of remission drive long-term clinical outcomes.
- The finalised results for **SPOTLIGHT** and **GLEAM**, in addition to latest developments for **FLAME** and **ENLIGHTEN**, were shared at the research updates meeting.

ISAR's impact on advancement to remission-focused research was demonstrated through the oral and poster presentations of the **SPOTLIGHT** study, which highlighted key findings and generated engagement with the wider ATS audience.

Professor David Price additionally presented '*The role of biologics in asthma remission*', underscoring the importance of setting a higher bar in asthma care towards the goal of remission.







Professor David Price presented '*Should Prescribing Expand from Specialists to Primary Care?*' during the Pulmonary Clinical Trials Workshop session on earlier intervention in asthma. The presentation highlighted the harm caused by delaying treatment until severe asthma develops, including irreversible damage to lungs and the burden of oral corticosteroid use, and emphasised the role of biologics in reducing steroid dependence and improving long-term outcomes through the achievement of remission. Key priorities identified included studies to better identify patients at risk of developing severe asthma, randomised trials evaluating biologics in high-risk and earlier severe asthma, and the implementation of structured care pathways to standardise the management of high-risk asthma.



ISAR poster presentation: Exciting findings were presented at EAACI highlighting characteristics of severe asthma patients in Poland in a poster presentation "Patient characteristics and treatment patterns in adults with severe asthma in Poland (**POLSAR**): a retrospective, single-center real-world cohort from **ISAR**"

UPCOMING EVENTS



We are pleased to announce that **six** abstracts have been accepted for presentation at ERS. Further developments and announcements for ERS will be shared soon!

ISAR Abstracts Accepted at ERS 2026:

Oral presentation

- **SHINE II:** Predictors of relapse at 24 months among ISAR patients in remission after 12 months on biologics.

Posters

- **ENLIGHTEN:** Assessment of quality improvement impact on long-term oral corticosteroid (LTOCS) use in ISAR.
- **SHINE I:** Relapse among International Severe Asthma Registry patients in remission 12 months after initiating biologics.
- **MOONLIGHT I:** ICS, SABA and triple therapy patterns of use following biologic initiation in severe asthma: real-world evidence from ISAR and OPCRD.
- **MOONLIGHT II:** Predictors of inhaled corticosteroid, SABA and triple-therapy reduction following biologic initiation in severe asthma: real-world evidence from ISAR and OPCRD.
- **FLAME:** Association between clinical and biological response to anti-IL5/5R biologic treatments in severe asthma.



ISAR's ***Registry-driven Data Quality Improvements*** project findings have been submitted to APSR, more updates to come soon!

We are looking forward to participating in several upcoming events where our team will be presenting our latest work. Hope to see you there!

---

https://www.isar.opcglobal.org/

CONTACT: isar@optimumpatientcare.org

Copyright (C) 2026. International Severe Asthma Registry (ISAR). All rights reserved.

If you prefer not to receive this newsletter, click here to unsubscribe.